Marieka V DeVuono1, Olivia La Caprara1, Gavin N Petrie2,3, Cheryl L Limebeer1, Erin M Rock1, Matthew N Hill2,3, Linda A Parker1. 1. Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, Canada. 2. Department of Cell Biology and Anatomy, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada. 3. Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.
Abstract
Introduction: Cannabinoid hyperemesis syndrome (CHS) is characterized by intense nausea and vomiting brought on by the use of high-dose Δ9-tetrahydrocannabinol (THC), the main psychotropic compound in cannabis. Cannabidiol (CBD), a nonpsychotropic compound found in cannabis, has been shown to interfere with some acute aversive effects of THC. In this study, we evaluated if CBD would interfere with THC-induced nausea through a 5-HT1A receptor mechanism as it has been shown to interfere with nausea produced by lithium chloride (LiCl). Since CHS has been attributed to a dysregulated stress response, we also evaluated if CBD would interfere with THC-induced increase in corticosterone (CORT). Materials and Methods: The potential of CBD (5 mg/kg, ip) to suppress THC-induced conditioned gaping (a measure of nausea) was evaluated in rats, as well as the potential of the 5-HT1A receptor antagonist, WAY-100635 (WAY; 0.1 mg/kg, ip), to reverse the suppression of THC-induced conditioned gaping by CBD. Last, the effect of CBD (5 mg/kg, ip) on THC-induced increase in serum CORT concentration was evaluated. Results: Pretreatment with CBD (5 mg/kg, ip) interfered with the establishment of THC-induced conditioned gaping (p=0.007, relative to vehicle [VEH] pretreatment), and this was reversed by pretreatment with 0.1 mg/kg WAY. This dose of WAY had no effect on gaping on its own. THC (10 mg/kg, ip) significantly increased serum CORT compared with VEH-treated rats (p=0.04). CBD (5 mg/kg, ip) pretreatment reversed the THC-induced increase in CORT. Conclusions: CBD attenuated THC-induced nausea as well as THC-induced elevation in CORT. The attenuation of THC-induced conditioned gaping by CBD was mediated by its action on 5-HT1A receptors, similar to that of LiCl-induced nausea.
Introduction: Cannabinoid hyperemesis syndrome (CHS) is characterized by intense nausea and vomiting brought on by the use of high-dose Δ9-tetrahydrocannabinol (THC), the main psychotropic compound in cannabis. Cannabidiol (CBD), a nonpsychotropic compound found in cannabis, has been shown to interfere with some acute aversive effects of THC. In this study, we evaluated if CBD would interfere with THC-induced nausea through a 5-HT1A receptor mechanism as it has been shown to interfere with nausea produced by lithium chloride (LiCl). Since CHS has been attributed to a dysregulated stress response, we also evaluated if CBD would interfere with THC-induced increase in corticosterone (CORT). Materials and Methods: The potential of CBD (5 mg/kg, ip) to suppress THC-induced conditioned gaping (a measure of nausea) was evaluated in rats, as well as the potential of the 5-HT1A receptor antagonist, WAY-100635 (WAY; 0.1 mg/kg, ip), to reverse the suppression of THC-induced conditioned gaping by CBD. Last, the effect of CBD (5 mg/kg, ip) on THC-induced increase in serum CORT concentration was evaluated. Results: Pretreatment with CBD (5 mg/kg, ip) interfered with the establishment of THC-induced conditioned gaping (p=0.007, relative to vehicle [VEH] pretreatment), and this was reversed by pretreatment with 0.1 mg/kg WAY. This dose of WAY had no effect on gaping on its own. THC (10 mg/kg, ip) significantly increased serum CORT compared with VEH-treated rats (p=0.04). CBD (5 mg/kg, ip) pretreatment reversed the THC-induced increase in CORT. Conclusions: CBD attenuated THC-induced nausea as well as THC-induced elevation in CORT. The attenuation of THC-induced conditioned gaping by CBD was mediated by its action on 5-HT1A receptors, similar to that of LiCl-induced nausea.
Authors: Erin M Rock; Cheryl L Limebeer; Gavin N Petrie; Lauren A Williams; Raphael Mechoulam; Linda A Parker Journal: Psychopharmacology (Berl) Date: 2017-04-20 Impact factor: 4.530
Authors: Marieka V DeVuono; Kelly M Hrelja; Lauren Sabaziotis; Alex Rajna; Erin M Rock; Cheryl L Limebeer; David M Mutch; Linda A Parker Journal: Neuropharmacology Date: 2018-09-07 Impact factor: 5.250
Authors: C L Limebeer; V K Vemuri; H Bedard; S T Lang; K P Ossenkopp; A Makriyannis; L A Parker Journal: Br J Pharmacol Date: 2010-09 Impact factor: 8.739
Authors: Amir Englund; Paul D Morrison; Judith Nottage; Dominic Hague; Fergus Kane; Stefania Bonaccorso; James M Stone; Avi Reichenberg; Rudolf Brenneisen; David Holt; Amanda Feilding; Lucy Walker; Robin M Murray; Shitij Kapur Journal: J Psychopharmacol Date: 2012-10-05 Impact factor: 4.153
Authors: Orrin Devinsky; Chloe Verducci; Elizabeth A Thiele; Linda C Laux; Anup D Patel; Francis Filloux; Jerzy P Szaflarski; Angus Wilfong; Gary D Clark; Yong D Park; Laurie E Seltzer; E Martina Bebin; Robert Flamini; Robert T Wechsler; Daniel Friedman Journal: Epilepsy Behav Date: 2018-07-11 Impact factor: 2.937